NO116851B - - Google Patents
Download PDFInfo
- Publication number
- NO116851B NO116851B NO163654A NO16365466A NO116851B NO 116851 B NO116851 B NO 116851B NO 163654 A NO163654 A NO 163654A NO 16365466 A NO16365466 A NO 16365466A NO 116851 B NO116851 B NO 116851B
- Authority
- NO
- Norway
- Prior art keywords
- ester
- pyridine
- atom
- compound
- formula
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 claims description 14
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- -1 3-pyridylcarbinol ester Chemical class 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 239000012433 hydrogen halide Substances 0.000 claims description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960004738 nicotinyl alcohol Drugs 0.000 description 2
- CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- RWEWEOKGGLQXPR-UHFFFAOYSA-N pyridine-2,5-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)N=C1 RWEWEOKGGLQXPR-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Analogifremgangsmåte ved fremstilling av den farmakologisk virksomme forbindelse pyridin-2, 5-dicarboxylsyre-di- (jB-pyridylcarbinolester) og dens salter.
Foreliggende oppfinnelse angår en analogifremgangsmåte ved fremstilling av pyridin-2yi5-dip,a.rboxylsy're-di-(P-pyridylcarbihoi-ester) og denne esters med vev forlikelige salter. •Den nye ester og dens salter er anvendbare som farmakologisk virksomme bestanddeler av preparater med ekstern eller intern vasodilaterende virkning, hvor god vannopploselighet er av stor betydning.
Det er fra svensk patentskrift nr.. 121.254 kjent at nicotinsyre-Ø-picolylester her ksrutvidende virkning og dessuten har blodtrykksenkende virkning. Denne ester har en relativt kortvarig gjennomblpdningaeffekt, som er beheftet :med intens hudirritesjon, og den h8r en LD^p-verdi. på 3500 mg/kg ved perorel administrering på mus.
Den nye ester som fremstilles ved enalogifremgengsmåtan ifdlge oppfinnelsen, utmerker seg ved en mildere men mer langvarig ker-utvidende virkning enn den kjente nicotinsyre-P-picolylester, hvilket er av verdi innen medisinen, spesielt for den gruppe pasienter som får kraftige bivirkninger av andre karutvidende midler. Den nye ester er lengt mindre giftig enn nevnte kjente ester, idet den her en LD^^-verdi hoyere enn 8000 ved peroral administrering på mus.
Med den nye ester oppnåes videre en kolesterolsenkende virkning. Forsok som er utfort på kaniner, har gitt tydelig virkning ved administrering ev 100 mg/kg. Også en minskning av FFA-innholdet, dvs. av innholdet av frie fettsyrer, oppnåes med den nye forbindelse. En tydelig effekt registreres på rotter ved en dose på 20 mg/kg.
Den nye pyridin-2, 5-dicarboxylsyre-di-(|3-pyridylcarbinolester) danner ved hydrolyse to molekyler P-pyridylcerbinol og et molekyl pyridin-2,5-dicarboxylsyre, som ved 2-decerboxylering gir 1 molekyl nicotinsyre.
Esteren og dens salter fremstilles ved at en pyridinforbindelse av formelen
i hvilken R-^betegner en hydroxylgruppe, et kloratom, et brometom eller en Ol^-^gruppe hvor betegner et metallatom, f.eks. natrium eller kalium, omsettes med en annen pyridinforbindelse av formelen
i hvilken R-. kan være en hydroxylgruppe, et kloratom, et bromatom eller en ORg-gruppe, hvor Ro her samme betydning som ovenfor, idet substituentene R-^og Hj velges således 8t der dennes en ester, som eventuelt
overfores på i og for seg kjent måte til et med vev forlikelig salt, f.eks. til hydrokloridet.
Reaksjonen mellom pyridinforbindelsene utfores fortrinnsvis
i et inert opplbsningsmiddel. Når R^eller Rj er klor eller brom, utfores reaksjonen fortrinnsvis i nærvær av ethydrogenhalogenid-opptagende middel bestående av et tertiært amin.
De folgende eksempler vil ytterligere illustrere oppfinnelsen.
Eksempel 1
I et 1000 ml' s reeksjonsapparat blandes 98 g (3-pyridylcarbinol med 86 g triethylemin og 300 g benzen under omrbring, hvoretter 90 g isocinchomeronsyre.diklorid opplost i 100 g benzen tildryppes under fortsatt omroring og kjoling. Omrbringen fortsettes ytterligere i 24 timer ved romtemperatur. Den herved dannede utfelning frafiltreres og vaskes med vann for bortskaffelse av triethyl-aminhydroklorid. Tilbakeblivende krystallmasse opplbses i 700 g kokende ethylalkohol med påfblgende behandling med aktivkull og filtrering. Ved langsom nedkjbling utkrystalliseres 95 g (67 %) pyridin-2, 5-dicerboxylsyre-di-(f3-pyridylcarbinolester) . Smeltepunkt 142 - 143°C
Eksempel 2
2515 g 3-klormethylpyridin og 21,1 g vannfritt netriumse.lt av isocinchomeronsyre settes til 300 ml dimethylformamid, og blan-dingen oppvarmes ved 100° i 24 timer. Dimethylformemidet av-J destilleres deretter ved redusert trykk. Den tilbakeblivende krystallmasse veskes med vann, tbrres og opplbses i 200 g kokende ethylalkohol. Den verme elkoholopplbsning behendles med aktivkull og filtreres. Ved evkjbling utkrystalliseres 16 g (48 %) pyridin-2,5-diC8rboxylsyre-di-(f3-pyridylC8rbinolester) med smeltepunkt 141°. - 143°C.
Claims (2)
1. Analogifremgangsmåte ved fremstilling av den farmakologisk virksomme forbindelse pyridin-2, 5-dicarboxylsyre-di-((3-pyridylcarbinolester) av formelen
og med vev forlikelige salter av denne forbindelse, karakterisert ved at en pyridinforbindelse av formelen
i hvilken R-^ betegner en hydroxylgruppe, et kloratom, et bromatom eller en C^-gruppe hvor R£ betegner et metallatom, f.eks. natrium eller kalium, omsettes med en annen pyridinforbindelse av formelen
i hvilken R, kan være en hydroxylgruppe, et kloratom, et brometom eller en 0R2~ gruppe hvor R2 her samme betydning som ovenfor, idet substituenterP R-j. og R^ velges således at der dannes en ester, som eventuelt overfores på i og for seg kjent måte til et med vev forlikelig selt, f.eks. til hydrokloridet.
2. Fremgangsmåte ifolge krev 1, karakterisert ved at der anvendes et tertiært amin som hydrogenhelogenid-opptegende middel når R-^ eller R^ er et kloratom eller et bromatom.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE08480/65A SE336334B (no) | 1965-06-28 | 1965-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO116851B true NO116851B (no) | 1969-06-02 |
Family
ID=20274189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO163654A NO116851B (no) | 1965-06-28 | 1966-06-27 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3403160A (no) |
| AT (1) | AT260931B (no) |
| BE (1) | BE683174A (no) |
| BR (1) | BR6680618D0 (no) |
| CH (1) | CH470390A (no) |
| DE (1) | DE1645916B1 (no) |
| DK (1) | DK116942B (no) |
| ES (1) | ES328896A1 (no) |
| FI (1) | FI46958C (no) |
| FR (1) | FR5763M (no) |
| GB (1) | GB1077850A (no) |
| IL (1) | IL25938A (no) |
| NL (1) | NL6608903A (no) |
| NO (1) | NO116851B (no) |
| SE (1) | SE336334B (no) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT163742B (de) * | 1946-06-04 | 1949-08-10 | Hoffmann La Roche | Verfahren zur Herstellung von Estern des Pyridyl-3-carbinols |
-
1965
- 1965-06-28 SE SE08480/65A patent/SE336334B/xx unknown
-
1966
- 1966-06-09 IL IL25938A patent/IL25938A/en unknown
- 1966-06-15 DE DE19661645916 patent/DE1645916B1/de active Pending
- 1966-06-16 AT AT574366A patent/AT260931B/de active
- 1966-06-17 FI FI661625A patent/FI46958C/fi active
- 1966-06-20 GB GB27514/66A patent/GB1077850A/en not_active Expired
- 1966-06-20 CH CH891366A patent/CH470390A/de not_active IP Right Cessation
- 1966-06-22 BR BR180618/66A patent/BR6680618D0/pt unknown
- 1966-06-22 US US559400A patent/US3403160A/en not_active Expired - Lifetime
- 1966-06-25 ES ES0328896A patent/ES328896A1/es not_active Expired
- 1966-06-27 NO NO163654A patent/NO116851B/no unknown
- 1966-06-27 FR FR67086A patent/FR5763M/fr not_active Expired
- 1966-06-27 BE BE683174D patent/BE683174A/xx unknown
- 1966-06-27 NL NL6608903A patent/NL6608903A/xx unknown
- 1966-06-28 DK DK334166AA patent/DK116942B/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE1645916B1 (de) | 1971-05-19 |
| IL25938A (en) | 1970-06-17 |
| CH470390A (de) | 1969-03-31 |
| NL6608903A (no) | 1966-12-29 |
| FI46958C (fi) | 1973-08-10 |
| SE336334B (no) | 1971-07-05 |
| FR5763M (no) | 1968-02-05 |
| FI46958B (no) | 1973-05-02 |
| US3403160A (en) | 1968-09-24 |
| BE683174A (no) | 1966-12-01 |
| DK116942B (da) | 1970-03-02 |
| GB1077850A (en) | 1967-08-02 |
| BR6680618D0 (pt) | 1973-05-24 |
| AT260931B (de) | 1968-03-25 |
| ES328896A1 (es) | 1967-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1287748A3 (ru) | Способ получени арилоксипропаноламинов или их фармакологически приемлемых солей (его варианты) | |
| EP0249950B1 (en) | Aromatic compounds | |
| JPS62149662A (ja) | Ｎ−含有複素環化合物 | |
| NO116851B (no) | ||
| KR102377981B1 (ko) | 폐 섬유증 치료용 조성물 | |
| DE949742C (de) | Verfahren zur Herstellung von N-Allylnormorphin aus Normorphin und Allylhalogenid | |
| EP0214437B1 (de) | Verfahren zur Herstellung von 1,4-Dihydropyridinderivaten über neue Zwischenprodukte | |
| JPS635025B2 (no) | ||
| JP6586692B2 (ja) | 新規キノン誘導体およびそれを有効成分とする抗トリパノソーマ剤 | |
| JPS61158980A (ja) | ８α‐アシルアミノエルゴリン類、その製法および医薬組成物 | |
| US2439818A (en) | Substituted esters of benzoic acid | |
| US2374367A (en) | Process for preparing therapeutically active substances | |
| US2322375A (en) | Process for preparing therapeutically active substances | |
| CN115785057B (zh) | 一种替卡格雷中间化合物及其盐的制备方法 | |
| US2030373A (en) | Derivatives of thiazole and process of preparing the same | |
| US3468889A (en) | O-and/or s-nicotinoyl diacylthiamines and acylation process for preparing the same | |
| KR800000813B1 (ko) | 몰포리논 유도체의 제조법 | |
| NO137892B (no) | Analogifremgangsm}te ved fremstilling av nye terapeutisk aktive basiske estere | |
| US2337572A (en) | Medicinal compound | |
| KR810000481B1 (ko) | 치환 n-(카르복시메틸)-3-아미노프로판-2-올의 제조방법 | |
| US2798073A (en) | Piperidine derivatives and preparation | |
| DE1695363C3 (de) | 1H-3.4 Dihydro-2,3 benzoxazin und dessen substituierte Derivate sowie Verfahren zur Herstellung dieser Verbindungen | |
| CH251026A (de) | Verfahren zur Herstellung von Nicotinsäure-B-picolylester. | |
| CH251023A (de) | Verfahren zur Herstellung von Nicotinsäure-B-picolylester. | |
| JP2861157B2 (ja) | 置換基を有するニコチン酸誘導体及びその製造方法 |